EU Approves New Bladder Cancer Therapy
The European Union has approved a new combination therapeutic agent for adults with operable bladder cancer, particularly for patients who cannot receive cisplatin chemotherapy. This is the first approval of its kind following a positive recommendation by the drug commission in May 2026.